Malaria vaccine candidate safe and immunogenic following first-in-human trials

Related content

• Research output

• First-in-human assessment of safety and immunogenicity of low and high doses of Plasmodium falciparum malaria protein 013 (FMP013) administered intramuscularly with ALFQ adjuvant in healthy malaria-naïve adults

  Research output: Contribution to journal › Article › peer-review